

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Proposed Single Technology Appraisal (STA)

## Tofacitinib for the treatment of moderate to severe active rheumatoid arthritis

## Provisional matrix of consultees and commentators (Pre-referral)

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Pfizer (tofacitinib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Afiya Trust</li> <li>• Arthritic Association</li> <li>• Arthritis &amp; Musculoskeletal Alliance (ARMA)</li> <li>• Arthritis Care</li> <li>• BackCare</li> <li>• Black Health Agency</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Leonard Cheshire Disability</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• National Rheumatoid Arthritis Society</li> <li>• Pain Concern</li> <li>• Pain Relief Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• STEPS Charity Worldwide</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Surgeons of Great Britain</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Health Professionals in Rheumatology</li> <li>• British Institute of Musculoskeletal Medicine</li> <li>• British Institute of Radiology</li> <li>• British Orthopaedic Association</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• Abbott Laboratories (adalimumab)</li> <li>• Actavis UK (azathioprine, sulfasalazine, penicillamine)</li> <li>• Alliance Pharmaceuticals (penicillamine)</li> <li>• Almus Pharmaceuticals (sulfasalazine)</li> <li>• Arrow Generics (azathioprine)</li> <li>• Astellas (auranofin)</li> <li>• AstraZeneca (chloroquine)</li> <li>• Focus Pharmaceuticals (azathioprine)</li> <li>• GlaxoSmithKline (azathioprine)</li> <li>• Kent Pharmaceuticals (azathioprine, sulfasalazine, penicillamine)</li> <li>• Merck Sharp &amp; Dohme (golimumab, infliximab)</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of tofacitinib for the treatment of moderate to severe active rheumatoid arthritis

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Pain Society</li> <li>• British Society for Rheumatology</li> <li>• British Society of Rehabilitation Medicine</li> <li>• Physiotherapy Pain Association</li> <li>• Primary Care Rheumatology Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Berkshire East</li> <li>• Powys Teaching Health Board</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Mylan (azathioprine, sulfasalazine, penicillamine)</li> <li>• Novartis Pharmaceuticals UK (ciclosporin)</li> <li>• Pfizer (etanercept, sulfasalazine)</li> <li>• Roche Products (tocilizumab)</li> <li>• Sandoz (azathioprine)</li> <li>• Sanofi (hydroxychloroquine, leflunomide, sodium aurothiomalate)</li> <li>• Teva UK (azathioprine, sulfasalazine, penicillamine)</li> <li>• UCB Pharma (certolizumab pegol)</li> <li>• Waymade Healthcare (sulfasalazine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Arthritis Research UK</li> <li>• Chronic Pain Policy Coalition</li> <li>• Cochrane Musculoskeletal Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guideline Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are:

manufacturers of comparator technologies;

Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.